Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 188

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 10
Chunk 188
---
 National Institute of Mental Health in Bethesda,
Maryland, where he pursued his research in Neurobiology.

57

Board
Composition

Our
business and affairs are managed under the direction of our board of directors, which currently consists of seven members. The number
of directors is determined by our board of directors, subject to the terms of our amended and restated articles of incorporation and
bylaws Our board of directors will continue to consist of seven members, and our directors will be elected for one-year terms.

Family
Relationships

There
are no family relationships among any of our directors and executive officers.

Director
Independence

Our
board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
his or her background, employment, and affiliations, our board of directors has determined that Matthew Pratt Whalen, Dr. Matthew Paul
Del Giudice, Dr. Craig Eagle and Edward MacPherson, do not have any relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director and are independent directors under the Nasdaq Listing Rules.

In
making these determinations, our board of directors considered the current and prior relationships that each non-employee director has
with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including
the transactions described in the section of this Annual Report titled “Certain Relationships and Related Party Transactions.” 

Committees
of the Board of Directors

Our
board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The
functions of these committees are described below. Members will serve on these committees until their resignation or until otherwise
determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from
time to time.

Audit
Committee

The
audit committee was established upon the effectiveness of our initial public offering on February 9, 2024 and consist of Matthew Pratt
Whalen, Edward MacPherson, and Dr. Matt Del Giudice, with Matthew Whalen serving as the chair of the audit committee. Mr. Whalen succeeded
Michael Jerman as Chair of the Audit Committee following Mr. Jerman’s resignation on November 18, 2024. Each member meets the requirements
for independence under the listing standards of Nasdaq and SEC rules and regulations, including Rule 10A-3(b)(1) under the Exchange